961 related articles for article (PubMed ID: 6197163)
41. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal antibodies to carcinoembryonic antigen: a systematic analysis of antibody specificities by using related normal antigens and evidence for allotypic determinants on carcinoembryonic antigen.
Kuroki M; Kuroki M; Koga Y; Matsuoka Y
J Immunol; 1984 Oct; 133(4):2090-7. PubMed ID: 6206151
[TBL] [Abstract][Full Text] [Related]
43. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
[TBL] [Abstract][Full Text] [Related]
44. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
45. [Cellular localization of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and carcinoembryonic antigen (CEA) in malignant germ cell tumors of the ovary using immunoperoxidase technique (author's transl)].
Obata N; Kodama S; Hando T; Takeuchi S
Nihon Sanka Fujinka Gakkai Zasshi; 1980 Jun; 32(6):757-66. PubMed ID: 6165791
[TBL] [Abstract][Full Text] [Related]
46. Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas.
Bodey B; Bodey B; Kaiser HE
Anticancer Res; 1997; 17(3C):2343-6. PubMed ID: 9216712
[TBL] [Abstract][Full Text] [Related]
47. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
49. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
Crawford ED; DeAntoni EP; Ross CA
J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
[TBL] [Abstract][Full Text] [Related]
50. Cross-linking of the carcinoembryonic antigen-like glycoproteins CD66 and CD67 induces neutrophil aggregation.
Kuijpers TW; van der Schoot CE; Hoogerwerf M; Roos D
J Immunol; 1993 Nov; 151(9):4934-40. PubMed ID: 8104998
[TBL] [Abstract][Full Text] [Related]
51. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
[TBL] [Abstract][Full Text] [Related]
52. Purification and characterization of carcinoembryonic antigen-related antigens in normal adult feces.
Kuroki M; Koga Y; Matsuoka Y
Cancer Res; 1981 Feb; 41(2):713-20. PubMed ID: 6160910
[TBL] [Abstract][Full Text] [Related]
53. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
54. Human chorionic gonadotropin in lung and lung tumors. Immunohistochemical study on unbalanced distribution of subunits.
Fukayama M; Hayashi Y; Koike M; Hajikano H; Endo S; Okumura H
Lab Invest; 1986 Oct; 55(4):433-43. PubMed ID: 2429065
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Dema A; Tudose N
Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
[TBL] [Abstract][Full Text] [Related]
56. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
Mai KT; Yazdi HM; Farmer J
Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
[TBL] [Abstract][Full Text] [Related]
57. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
58. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
[TBL] [Abstract][Full Text] [Related]
59. Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors.
Papotti M; Paties C; Peveri V; Moscuzza L; Bussolati G
Basic Appl Histochem; 1989; 33(1):25-9. PubMed ID: 2471501
[TBL] [Abstract][Full Text] [Related]
60. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
